Novo Nordisk more than doubles its stockpile amid Brexit fears

25 January 2019

Danish diabetes giant Novo Nordisk (NOV: N) has sad that it is doubling its UK stocks of insulin in preparation for a possible “no-deal” Brexit.

By March 29, the planned date of the UK’s departure from the trading bloc of European nations, Novo Nordisk said it expects to have about 17 weeks worth in its stockpile, two and a half times its usual reserve levels.

Replying to a Tweet from a concerned patient, the company said it would “continue to build stock ahead of 29 March.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK